Table 3 .
Predictors of NIPPV success, univariate and multivariate analysis
| Variables | Univariable OR (95% CI) |
P value | Multivariable OR (95% CI) |
P value |
|---|---|---|---|---|
| Age, yearsa | 0.94 (0.89–1) | 0.041 | 1.11 (0.95–1.28) | 0.183 |
| Female sex (vs. male) | 0.58 (0.17–1.94) | 0.375 | – | – |
| Atrial fibrillation | 0.62 (0.17–2.22) | 0.463 | ||
| Cardiovascular disease | 0.57 (0.18–1.79) | 0.337 | – | – |
| Chronic kidney disease | 0.25 (0.05–1.33) | 0.103 | – | – |
| Cognitive impairment | 0.46 (0.08–2.64) | 0.383 | – | – |
| COPD | 0.81 (0.2–3.34) | 0.776 | – | – |
| Diabetes mellitus | 0.88 (0.24–3.28) | 0.852 | – | – |
| Hypertension | 0.9 (0.29–2.77) | 0.854 | – | – |
| Immunodeficiency | 2.7 (0.23–31.89) | 0.430 | – | – |
| Malignancy | 0.22 (0.02–2.03) | 0.181 | – | – |
| Stroke | 0.37 (0.7–2.03) | 0.250 | – | – |
| Total number of comorbiditiesa | 0.73 (0.49–1.09) | 0.122 | – | – |
| SOFA scorea | 0.76 (0.47–1.26) | 0.290 | – | – |
| PaO2/FiO2 before NIPPV, mm Hga | 1 (0.99–1.01) | 0.511 | – | – |
| PaO2/FiO2 24–48 h after NIPPV initiation, mm Hga | 1.01 (1–1.03) | 0.008 | 1.02 (1–1.03) | 0.015 |
| NIPPV CPAP (vs. BiPAP) | 2.7 (0.85–8.57) | 0.091 | – | – |
| Antibiotics | 0.77 (0.1–5.94) | 0.801 | – | – |
| Corticosteroids | 4.75 (1.14–19.83) | 0.033 | 15.4 (1.79–132.57) | 0.013 |
| Tocilizumab | 5.52 (1.53–19.86) | 0.009 | 6.35 (0.88–45.86) | 0.067 |
| DNI order | 0.18 (0.05–0.61) | 0.006 | 0.03 (0.001–0.57) | 0.020 |
aPer 1-unit increase